US Patent

US8513259 — Non-sedating antihistamine injection formulations and methods of use thereof

Method of Use · Assigned to JDP Therapeutics Inc · Expires 2030-02-11 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects injectable formulations of non-sedating antihistamines, such as cetirizine, and methods for using them to treat acute urticaria or angioedema.

USPTO Abstract

Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2636 — cetirizine-hydrochloride

Patent Metadata

Patent number
US8513259
Jurisdiction
US
Classification
Method of Use
Expires
2030-02-11
Drug substance claim
No
Drug product claim
No
Assignee
JDP Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.